Kymera Therapeutics (KYMR) Competitors

Kymera Therapeutics (NASDAQ:KYMR) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, community ranking, analyst recommendations, valuation, media sentiment and institutional ownership.

Does the MarketBeat Community believe in KYMR or ASND?

Ascendis Pharma A/S received 386 more outperform votes than Kymera Therapeutics when rated by MarketBeat users. Likewise, 66.57% of users gave Ascendis Pharma A/S an outperform vote while only 52.94% of users gave Kymera Therapeutics an outperform vote.

Company	Underperform	Outperform
Kymera Therapeutics	Outperform Votes 54 52.94%	Underperform Votes 48 47.06%
Ascendis Pharma A/S	Outperform Votes 440 66.57%	Underperform Votes 221 33.43%

Is KYMR or ASND more profitable?

Ascendis Pharma A/S has a net margin of -130.33% compared to Kymera Therapeutics' net margin of -191.26%. Ascendis Pharma A/S's return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-191.26%	-24.96%	-20.27%
Ascendis Pharma A/S	-130.33%	N/A	-48.77%

Does the media favor KYMR or ASND?

In the previous week, Kymera Therapeutics and Kymera Therapeutics both had 9 articles in the media. Ascendis Pharma A/S's average media sentiment score of 0.67 beat Kymera Therapeutics' score of 0.57 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, KYMR or ASND?

Kymera Therapeutics has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

Which has stronger valuation and earnings, KYMR or ASND?

Kymera Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$78.59M	33.46	-$146.96M	-$2.34	-17.35
Ascendis Pharma A/S	$327.43M	23.75	-$521.07M	-$8.08	-15.86

Do analysts prefer KYMR or ASND?

Kymera Therapeutics currently has a consensus price target of $55.38, indicating a potential upside of 36.36%. Ascendis Pharma A/S has a consensus price target of $192.07, indicating a potential upside of 49.90%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Summary

Ascendis Pharma A/S beats Kymera Therapeutics on 9 of the 15 factors compared between the two stocks.